Prevention of type 1A diabetes mellitus

Endocrine Practice

Volumn 18, Issue 5, 2012, Pages 745-749

  Eisenbarth, George S ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BCG VACCINE; C PEPTIDE; CD20 ANTIBODY; CD3 ANTIBODY; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; HLA DQ2 ANTIGEN; HLA DQ8 ANTIGEN; HLA DQB1 ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; INSULIN; NICOTINAMIDE; THYMOCYTE ANTIBODY;

BCG VACCINATION; CELL DESTRUCTION; DIABETES MELLITUS; DISEASE COURSE; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RELEASE; LOW DRUG DOSE; NONHUMAN; ONSET AGE; PANCREAS ISLET BETA CELL; REVIEW; TYPE 1A DIABETES MELLITUS;

EID: 84867344356     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP12080.OR     Document Type: Review

References (48)

1. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendo-crine deficiencies. Lancet. 1974;2:1279-1283.
2. Srikanta S, Ganda OP, Eisenbarth GS, Soeldner JS. Islet cell antibodies and beta-cell function in monozygotic triplets and twins initially discordant for type I diabetes mellitus. N Engl J Med. 1983;308:322-325.
3. Eisenbarth GS. Type I diabetes mellitus. A chronic auto-immune disease. N Engl J Med. 1986;314:1360-1368.
4. Palmer JP, Asplin CM, Clemons P, et al. Insulin antibod-ies in insulin-dependent diabetics before insulin treatment. Science. 1983;222:1337-1339.
5. Baekkeskov S, Aanstoot HJ, Christgau S, et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase [Erratum in Nature. 1990;347:782]. Nature. 1990;347:151-156.
6. Wenzlau JM, Moua O, Sarkar SA, et al. SlC30A8 is a major target of humoral autoimmunity in type 1 diabetes and a predictive marker in prediabetes. Ann N Y Acad Sci. 2008;1150:256-259.
7. Lan MS, LU J, Goto Y, Notkins AL. Molecular cloning and identification of a receptor-Type protein tyrosine phos-phatase, IA-2, from human insulinoma. DNA Cell Biol. 1994;13:505-514.
8. Wang L, Lovejoy NF, Faustman DL. Persistence of pro-longed C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay. Diabetes Care. 2012;35:465-470.
9. Concannon P, Rich SS, Nepom GT. Genetics of type 1A diabetes. N Engl J Med. 2009;360:1646-1654.
10. Sosenko JM, Skyler JS, Krischer JP, et al. Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-Type 1 (DPT-1). Diabetes. 2010;59:2386-2389.
11. Gianani R, Campbell-Thompson M, Sarkar SA, et al. Dimorphic histopathology of long-standing childhood-onset diabetes. Diabetologia. 2010;53:690-698.
12. Eisenbarth GS. Banting Lecture 2009: An unfinished jour-ney: Molecular pathogenesis to prevention of type 1A dia-betes. Diabetes. 2010;59:759-774.
13. Nakayama M, Abiru N, Moriyama H, et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature. 2005;435:220-223.
14. Vafiadis P, Bennett ST, Todd JA, Nadeau J, et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet. 1997;15:289-292.
15. Steck AK, Johnson K, Barriga KJ, et al. Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagno-sis of type 1 diabetes: Diabetes autoimmunity study in the young. Diabetes Care. 2011;34:1397-1399.
16. Bell GI, Horita S, Karam JH. A polymorphic locus near the human insulin gene is associated with insulin-depen-dent diabetes mellitus. Diabetes. 1984;33:176-183.
17. Pugliese A, Zeller M, Fernandez A Jr, et al. The insulin gene is transcribed in the human thymus and transcription levels correlate with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type I diabetes. Nat Genet. 1997;15:293-297.
18. Achenbach P, Koczwara K, Knopff A, Naserke H, Ziegler AG, Bonifacio E. Mature high-Affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest. 2004;114:589-597.
19. Keenan HA, Sun JK, Levine J, et al. Residual insulin pro-duction and pancreatic b-cell turnover after 50 years of dia-betes: Joslin Medalist Study. Diabetes. 2010;59:2846-2853.
20. In't Veld P, Lievens D, De Grijse J, et al. Screening for insulitis in adult autoantibody-positive organ donors. Diabetes. 2007;56:2400-2404.
21. Erlich H, Valdes AM, Noble J, et al. HLA DR-DQ hap-lotypes and genotypes and type 1 diabetes risk: Analysis of the type 1 diabetes genetics consortium families. Diabetes. 2008;57:1084-1092.
22. Baschal EE, Aly TA, Babu SR, et al. HLA-DPB1*0402 protects against type 1A diabetic autoimmunity in the high-est risk DR3-DQB1*0201/DR4- DQB1*0302 DAISY pop-ulation. Diabetes. 2007;56:2405-2409.
23. Baschal EE, Eisenbarth GS. Extreme genetic risk for type 1A diabetes in the post-genome era. J Autoimmun. 2008;31:1-6.
24. Baschal EE, Baker PR, Eyring KR, Siebert JC, Jasinski JM, Eisenbarth GS. The HLA-B 3906 allele imparts a high risk of diabetes only on specific HLA-DR/DQ haplo-Types. Diabetologia. 2011;54:1702-1709.
25. Howson JM, Walker NM, Clayton D, Todd JA; Type 1 Diabetes Genetics Consortium. Confirmation of HLA class II independent type 1 diabetes associations in the major histocompatibility complex including HLA-B and HLA-A. Diabetes Obes Metab. 2009;11(Suppl 1):31-45.
26. Verge CF, Gianani R, Kawasaki E, et al. Prediction of type I diabetes in first-degree relatives using a combina-Tion of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes. 1996;45:926-933.
27. Bingley PJ, Christie MR, Bonifacio E, et al. Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes. 1994;43:1304-1310.
28. Skyler JS. Immune intervention for type 1 diabetes mel-litus. Int J Clin Pract Suppl. 2011;170:61-70.
29. Shields BM, McDonald TJ, Ellard S, Campbell MJ, Hyde C, Hattersley AT. The development and valida-Tion of a clinical prediction model to determine the prob-Ability of MODY in patients with young-onset diabetes. Diabetologia. 2012;55:1265-1272.
30. Roep BO, Atkinson M, von Herrath M. Satisfaction (not) guaranteed: Re-evaluating the use of animal models of type 1 diabetes. Nat Rev Immunol. 2004;4:989-997.
31. Wherrett DK, Bundy B, Becker DJ, et al; Type 1 Diabetes TrialNet GAD Study Group. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: A randomised double-blind trial. Lancet. 2011;378:319-327.
32. Klingensmith G, Allen H, Hayward A, et al. Vaccination with BCG at diagnosis does not alter the course of IDDM. Diabetes. 1997;46(Suppl 1):193A [Abstract].
33. Michels AW, Eisenbarth GS. Immune intervention in type 1 diabetes. Semin Immunol. 2011;23:214-219.
34. Couri CE, Oliveira MC, Stracieri AB, et al. C-peptide levels and insulin independence following autologous non-myeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2009; 301:1573-1579.
35. Couri CE, Voltarelli JC. Stem cell-based therapies and immunomodulatory approaches in newly diagnosed type 1 diabetes. Curr Stem Cell Res Ther. 2011;6:10-15.
36. Herold KC, Bluestone JA. Type 1 diabetes immunother-Apy: Is the glass half empty or half full? Sci Transl Med. 2011;3:95FS1.
37. Pescovitz MD, Torgerson TR, Ochs HD, et al; Type 1 Diabetes TrialNet Study Group. Effect of rituximab on human in vivo antibody immune responses. J Allergy Clin Immunol. 2011;128:1295-1302.e5.
38. Orban T, Bundy B, Becker DJ, et al. Co-stimulation mod-ulation with abatacept in patients with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled trial. Lancet. 2011;378:412-419.
39. Herold KC, Gitelman S, Greenbaum C, et al; Immune Tolerance Network ITN007AI Study Group. Treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin pro-duction for up to 5 years. Clin Immunol. 2009;132:166-173.
40. Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest. 2005;115:2904-2913.
41. Bresson D, von Herrath M. Moving towards efficient therapies in type 1 diabetes: To combine or not to combine? Autoimmun Rev. 2007;6:315-322.
42. Knip M, Virtanen SM, Seppä K, et al Finnish TRIGR Study Group. Dietary intervention in infancy and later signs of beta-cell autoimmunity. N Engl J Med. 2010;363: 1900-1908.
43. Redondo MJ, Jeffrey J, Fain PR, Eisenbarth GS, Orban T. Concordance for islet autoimmunity among monozy-gotic twins. N Engl J Med. 2008;359:2849-2850.
44. Writing Group for the SEARCH for Diabetes in Youth Study Group, Dabelea D, Bell RA, et al. Incidence of diabetes in youth in the United States. JAMA. 2007; 297:2716-2724.
45. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: A jack of all trades, master of regulation. Nat Immunol. 2008; 9:239-244.
46. Michels AW, Ostrov DA, Zhang L, et al. Structure-based selection of small molecules to alter allele-specific MHC class II antigen presentation. J Immunol. 2011;187: 5921-5930
47. Stadinski B, Kappler J, Eisenbarth GS. Molecular tar-geting of islet autoantigens. Immunity. 2010;32:446-456.
48. Liu Z, Cort L, Eberwine R, Herrmann T, et al. Prevention of type 1 diabetes in the rat with an allele-specific anti-T-cell receptor antibody: Vß13 as a therapeutic target and biomarker. Diabetes. 2012;61:1160-1168.